Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits
· Hikma has entered into a preliminary class settlement agreement that resolves the majority of its Xyrem® (sodium oxybate) antitrust class action cases in the US
· Under the agreement and subject to court approval, Hikma would pay up to $50 million in cash
London, 8 May 2025 – Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (the Company), today announced that it has reached an agreement to resolve the majority of the class action antitrust lawsuits brought against the Company by third-party payors in the US who have purchased or been billed for Xyrem® (sodium oxybate). These matters have been previously disclosed as contingent liabilities in our financial disclosures.
“We are pleased to have reached a settlement agreement that protects the Company’s interests and provides clarity to our stakeholders,” said Sam Park, Hikma’s General Counsel. “We are proud to have facilitated patients’ access to a lower-cost authorised generic version of this essential medicine, years ahead of its patent expiration.”
The settlement is subject to court approval and resolves the majority of the cases pending against Hikma. If all conditions are satisfied, Hikma agrees to pay up to $50 million in cash.
This settlement is not an admission of wrongdoing or liability, and Hikma will continue to defend itself vigorously against any litigation that this settlement does not resolve.